Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Oct 2026: Stryker agreed a preferred equity investment of about $400m in CMR Surgical, with an exclusive option to buy 100% of the company, subject to regulatory approvals. This followed a $200m+ equity and debt round in Apr 2025.
Data breaches, cyber incidents, regulator action and assurance status.
Jun 2026: CMR Surgical began a US recall (FDA Class 2) of two Versius surgeon consoles after secure boot was not enabled in manufacturing, which it said presented a potential cybersecurity risk; it is configuring secure boot on affected units. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Jun 2026: FDA Class 2 recall of two US Versius surgeon consoles over secure boot not being enabled (open as posted). Aug 2025: Germany's BfArM published a CMR Surgical advisory notice for the Versius Surgeon Console; its content was not stated on the summary page.
Contract delivery, go-lives, terminations and disputes.
No contract terminations, disputes or troubled implementations involving CMR Surgical found in HSH's search of the last 24 months. Apr 2025: the company said Versius had been used in over 30,000 cases in 30+ countries.